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INTRODUCTION 
 
 
Tuberculosis is, one of the oldest disease known to affect humans, is a 
major cause of death worldwide. This is a bacterial infection, which is caused by 
mycobacterium tuberculosis  . Usually affect the lungs, although other organs are 
involved in up to one-third of cases. If properly treated, tuberculosis caused by 
drug susceptible strains is curable in virtually all cases. Transmission usually  take 
place through the airborne spread of droplet nuclei produced by patients with 
infectious pulmonary tuberculosis. 
Diabetes and Pulmonary Tuberculosis : 
A variety of diseases and conditions favour the development of active 
tuberculosis. Likewise relative risk of developing pulmonary tuberculosis of all 
types and bacteriologically confirmed cases were 4 to 5 times higher in the 
diabetic patients than the matched controls. So diabetes was associated with an 
increased risk of pulmonary tuberculosis. Henceforth patients with Diabetes 
mellitus may be important targets for pulmonary Tuberculosis. 
As well, effort to diagnose, detect and treat, Diabetes mellitus may have a 
beneficial impact on pulmonary tuberculosis control. 
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Historical overview of the Tuberculosis  
Gutierrez and her colleagues at the Pasteur institute have concluded that, 
the progenitor of mycobacterium tuberculosis emerged from an array of 
mycobacterial species about 3 million years ago, presumably infecting early 
hominids and other primates in prehistoric times. It seems likely that all modern 
members of the mycobacterium tuberculosis complex evolved from a common 
ancestor 15,000 – 20,000 years ago10. 
Tuberculosis is a disease that has afflicted human kind throughout 
recorded history. Spinal lesion that are highly suggestive of tuberculosis have 
been observed in a skeleton recovered from a grave near Heidelberg that dates 
from 5000 BC; a skeleton excavated from the arena candide cave in Liguria, Italy 
that dates from 4000 BC; and similarly ancient graves in Denmark and the Jordan 
valley. Mycobacterium tuberculosis DNA has been recovered from a pre-
Columbian mummy from Peru11.  
The earliest archaeological evidence of human TB comes from Egyptian  
art and mummies, there is ample evidence of spinal TB (Pott’s disease) as early as 
5,500 years ago. There are unequivocal references to TB in the old testament 
books of Deuteronomy and Leviticus at the time when jews were in exile in 
Egypt. 
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There is General agreement that TB first appeared as a human disease in 
East Central Africa and that it travelled with early peoples as they migrated into 
Asia minor and across the globe. There are imprecise prehistoric references to TB 
from INDIA and CHINA, but no archaeological evidence.  
Tuberculosis in India has worst scourge bordering on silent genocide. 
Despite the fact BCG vaccination is given at birth all over the country, TB 
remains the biggest killer disease in India. India bears 28.4% of the entire world’s 
TB burden. 
There have been references to TB in the Vedas and it was called 
“Rajayakshma”. 
In the Krishna Yajurveda Samhita, there is reference to how Soma (Moon) 
had been affected by ‘Yakshma’, since soma, who affected by yakshma’ it came 
to be known as Rajayakshma – Vagabhata, Ast-s, and Ast-hrd, Nidana (Vol.1-2)22. 
The great Indian physician SUSRUTA in 600 A.D. while (Avicenna 780-
1027 AD) had commented that phthisis frequently complicated diabetes. 
In classical Greece, Hippocrates, Plato and Aristotle described TB, and  
the word “Phthisis” for pulmonary TB in Greek, which means to melt or waste 
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away. Aristotle noted its contagious nature, but it was not until Koch discovered 
the tubercle bacillus in 1882.   
Phthisis makes its attacks chiefly between the age of eighteen and thirty 
five; Hippocrates wrote. Tuberculosis was described by GALAN, the Greek 
Physician who settled in Rome and became its preeminent physician. He 
Recommended Fresh air, milk and sea voyages for his TB patients, treatment 
modalities that would persist well into the nineteenth and twentieth centuries. 
There is also abundant evidence that scrofula – TB of the Cervical lymph 
nodes- was common in mediaeval Europe. Beginning with the Frankish king 
clovis in 496, European rulers practiced healing of this affliction by the royal 
touch, and later rulers supported some of the large expenses of the throne by 
charging the thousands of supplicants who sought their cures. 
Increasing urbanization led to rising TB incidences. St. Francis died of TB 
in 1226; Baruch Spinoza succumbed in 1677. 
In 1660 JOHN BUNYON called TB “The captain among these                                 
men of Death”. At the time, case rates in London probably reached 1000-1250/ 
100,000/ year4. 
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As the epidemic wave of TB crested in Europe and North America in the 
eighteenth and nineteenth centuries, the disease became Romanticized. 
Charles Dickens wrote, “There is a dread disease…. In which the struggle 
between body and soul is so gradual, quiet, and solemn…. (that as) the mortal part 
wastes and wither away, so the spirot grows light and sanguine5. 
Although TB had reached most of the globe in prehistoric times, it had 
long since receded from the Americas and much of Africa, leaving the peoples of 
those regions immunologically naive with Respect to Mycobacterium 
Tuberculosis. 
Tuberculosis crested in Europe and North America at the middle of the 
nineteenth century and has been falling since that time to present historic low case 
rate.  
Thomas Mckeown, a highly Respected population scientist, examined 
many possible causes for this decline and concluded that better nutrition played 
the major role. 
Leonard Wilson argued that removal of infectious individuals to treatment 
facilities was a major factor. E.R.N. Grigg concluded that genetic herd immunity 
which developed as a Result of selection influenced by the high death rates in 
young TB adults resulted in the falling incidence10.                                                                                   
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Discovery of the causes         : 
In 1720 Benjamin marten published a remarkably clairvoyant book 
entitled, A new theory of consumption; More Especially of the phthisis or 
consumption of the lungs. The original and Essential cause, then wrote, may 
possibly be some certain species of animalcula or wonderful minute living 
creatures9. 
Jean – Antoine Villemin , a French military surgeon, who convincingly 
demonstrated the infectious nature of TB. 
The Great pioneer of bacteriology ROBERT KOCH, demonstrated 
conclusively that a bacterium, which he called Bacillus Tuberculosis and is now 
known as Mycobacterium tuberculosis is the etiological agent of TB. His dramatic 
presentation of his findings on 24 March 1882 was immediately hailed, and he 
was acclaimed throughout the world. 
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Diagnosis : 
Koch’s studies of TB led to his report of tuberculin, as noted below. 
Viennese paediatrician Clemens Freiherr von pirquet, one of the Founders of the 
Science of allergy, developed the intracutaneous  tuberculin test much as we know 
it today2. 
The Further work of Florence seibert and others in the 1930s led to the 
production of tuberculin – purified protein derivative, the antigen used today for 
tuberculin skin testing. 
In November 1895, Conrad wilhelm Rontgen, a distinguished physicist 
interested in Radiation, discovered X-rays. With  in a month he had imaged his 
wife’s hand. The American inventor, Thomas Alva Edison developed the first 
practical fluoroscope, making clinical Radiology a practical reality. 
Francis Williams Reported on the Fluoroscopic examination of the lungs 
in more than 100 patients at the Boston city Hospital. During the second world  
war , France, the united state, and Germany introduced Radiographic Screening of 
military Recruits for TB. 
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The Search for a cure : 
Koch, produce, tuberculin, a concentrated bacteria free, filtrate of liquid 
cultures of mycobacterium tuberculosis; it became of great importance in the 
diagnosis of tuberculosis infection. 
None of these measures benefitted the dying poet john keats, however, 
Herman Brehmer opened the first sanatorium for TB patients in Goerbersdorf in 
the silesan Mountains of Prussia in 1859. 
As early as 1696, Giorgio Baglivi observed that a patient with pulmonary 
TB improved after a sword wound Resulted in a pneumothorax. Pneumothorax 
was first introduced for therapy by Carlo Forlanini in 1894 with beneficial 
Results. 
The procedure was Rapidly accepted and widely used to collapse 
pulmonary cavities during the next 50 years. Pneumoperitoneum was used for 
lower lobe cavities. About the same time, thoracoplasty came into use in those 
cases in which satisfactory collapse could not be achieved by pneumothorax. 
In the late 1800s, before chemotherapeutic agents had been discovered, 
patients with tuberculosis were isolated in sanatoriums for nutrition and rest. Lung 
collapse therapy was performed by pneumothorax or various surgical techniques 
that frequently left patients disfigured for life.  
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Chemotherapy: 
The idea that it might be possible to find an agent that was specifically 
curative was espoused by paul Ehrlich, who heard Koch’s presentation. His work 
led to treatment for trypanosomiasis and syphilis. 
In 1932, Gerhardt Domagk, a pathologist working at the laboratories of 
Bayer, the German chemical company discovered prontosil, the first 
sulphonamide, Domagk continued to work, and his efforts led to thioacetazone, 
the first mycobacteriostatic drug. Shortly there after Jorgen Lehman in Sweden 
discovered Paraamino Salicylic acid (PAS) also mycobacteriostatic. Selman 
Waksman with his junior colleagues Albert schatz and Elizabeth Bugie discovered 
streptomycin in 1943, the first mycobacteriocidal drug and an early member of a 
class of drugs that Waksman called Antibiotics. 
Isoniazid was discovered almost simultaneously by three pharmaceutical 
companies in 1952 and Rifampicin in 1963. 
Thus, in the 60 years since the introduction of the first effective drugs for 
the treatment of tuberculosis, the care of these patients has been transformed from 
long hospitalization and a lifetime of fear of relapse to a relatively short outpatient 
treatment regimen and cure.  
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The challenge today is not so much how to treat tuberculosis as how to 
ensure that patients receive the proper treatment. Failure to deliver proper care is 
the major cause for the development of drug resistant strains and the feat for the 
recrudescence of this dreaded malady. Thus, directly observed therapy i.e., DOTS 
has been adopted as the preferred method for insuring completions of effective 
therapy.  
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Prevention and Control : 
With knowledge of Edward Jenner’s Vaccinia  prevention of small pox 
and Louiz pasteur’s immunization treatment of Rabies, Albert Calmette decided to 
turn his effort at the Pasteur institute in Lille, France to developing a vaccine 
agent. 
In 1921, Calmette, now in paris, was Ready to try the vaccine known as 
Bacillus calmette Guerin (BCG) in a human subject. 
Current control strategies in most nations emphasize treatment under direct 
observation using optimal drug Regimens to reduce the further spread of 
tuberculosis bacilli. Despite the discovery of the cause of the tuberculosis, and the 
development of effective chemotherapy in the 1950s, tuberculosis continues to be 
a major pulmonary pathogen and is a leading cause of infectious death in adults 
worldwide. 
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AIM OF THE STUDY 
 
 
1. To study the current  prevalence of pulmonary tuberculosis in diabetic 
patients.  
2. To study the spectrum of its distribution in terms of sex and age. 
3. To study the symptomatology of subjects with diabetes alone and with 
pulmonary tuberculosis. 
4. To study the hematological, biochemical and Radiological changes in 
patients with diabetes mellitus and pulmonary tuberculosis. 
5. To study the pulmonary tuberculosis relationship with glycemic status. 
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REVIEW OF THE LITERATURE 
 
 
The lung is the most commonly affected organ in tuberculosis. In the 2004 
CDC surveillance reports, 79.5% of the newly diagnosed cases of tuberculosis had 
lung involvement. Similar rates of pulmonary involvement are found in both 
immunocompetent and immunocompromised hosts. Such as those with Human 
Immuno-deficiency Virus infection7. 
Patients with Diabetes mellitus are at increased risk of developing active 
TB, but this risk, which may be fivefold or more, varies according to the 
background prevalence of TB and various host factors, including the patients age 
and sex, body mass, duration of diabetes and most importantly, adequacy of 
glycemic control.  
The worldwide prevalence of diabetes has raisen dramatically over the past 
2 decades, from an estimated 30 million cases in 1985 to 177 million in 2000. 
Based on current trends, more than 360 million individuals will have diabetes by 
the year of 2030. The prevalence of Type 2 diabetes is rising much more rapidly 
because of increasing obesity and reduced activity levels as countries become 
more industrialized. 
The prevalence of type 2 diabetes and its harbinger, IGT, is highest in 
certain pacific islands, intermediate in countries such as INDIA and the United 
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States and relatively low in Russia. A recent estimate suggested that diabetes was 
the 5th leading cause of death worldwide, and was responsible for almost 3 million 
deaths annually (1.72-5.2% of death worldwide). 
Individuals with diabetes mellitus have a great frequency and severity of 
infection. The reasons for these include incompletely defined abnormalities in cell 
mediated immunity and phagocytes function associated with hyperglycemia, as 
well as diminished vascularization. So, a high prevalence of pulmonary 
tuberculosis was found in diabetic patients. This pulmonary tuberculosis is due to 
mycobacterium tuberculosis, is a rod-shaped, non-spore forming, thin aerobic 
bacterium measuring 0.5 micrometer/3 micrometer. Mycobacteria, including 
Mycobacterium Tuberculosis, are often neutral on gram’s staining. However, once 
stained, the bacilli cannot be decolorized by acid alcohol; this characteristic 
justifies there classification as Acid-Fast Bacilli. 
 More than 5 million new cases of tuberculosis (all forms, both pulmonary 
and extra-pulmonary) were reported to the WHO in 2005; more than 90% of cases 
were reported from the developing countries. However, because of insufficient 
case detection and incomplete notification, reported cases represent only 
approximately 60% of the total estimated cases. 
12The WHO estimated that 8.8 million new cases of tuberculosis occurred 
worldwide in 2005, 95% of them in developing countries of Asia (4.9 million); 
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Africa (2.6 million); the middle-east (0.6 million) and Latin America (0.4 
million). It is further estimated that 1.6 million deaths from tuberculosis occurred 
in 2005, 95% of them in developing countries. Estimates of tuberculosis incidence 
rates and number of deaths due to tuberculosis in 2005 in India is 100- 
299/100,000 population and more than 100,000, respectively. 
In 1883, Windle autopsied 333 known diabetic subjects and observed 
pulmonary tuberculosis, in more than 50% of them. In a classic study, Root 
Reported that 2.8% of 1373 hospitalized diabetics had pulmonary Tuberculosis of 
the 750 juvenile diabetics, 1.6% had tuberculosis as compared to 0.12% among 
school children. After studying the association between Diabetes and 
Tuberculosis, he made the following observation2. 
i) The development of TB occured  ten times more frequently in 
juvenile diabetics. 
ii) In 85% of the patients, Tuberculosis had developed after the onset 
of Diabetes. 
iii) The occurence of pulmonary Tuberculosis increased with the 
duration of Diabetes. 
3The Philadelphia survey revealed that 8.4% of the 3,106 diabetes had 
pulmonary tuberculosis as compared to 4.3% of the 71,767 presumably healthy 
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industrial workers. TB was present in 17% of the DM who had had the disease for 
more than 10 yrs. Compared to 5% in DM with less than 10 yrs of the disease. 
A higher prevalence of TB was found in diabetes patients requiring more 
than 40 units of insulin per day. 
In countries like INDIA, diabetes remains one of the most important Risk 
factor predisposing towards tuberculosis, along with malnutrition, alcoholism and 
HIV infection. The prevalence of pulmonary tuberculosis in diabetics in INDIA 
varies from 3.3% to 8.3% about 4 times that of General population6. 
The purported relationship between DM and TB dates back to Roman 
times. In an extensive Recent Review of the epidemiology of TB Rieder et al. 
have drawn as 3 larger survey’s from 1950s. It suggest relative risk of TB in 
individuals with diabetes that is 2-3.6 times that in those of non DM. 
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Factors influencing Susceptibility to Tuberculosis in diabetic patients: 
i) Age and Duration of diabetes : 
a. Diabetes over the age of 40 years are at increased risk of 
developing TB and a longer duration of diabetic disease 
predisposes to TB in all age group19. 
ii) Sex : 
a. Male diabetics are generally considered to be at greater risk of TB 
than female. 
iii) Glycemic Control  : 
Increased risk of smear positive disease has been demonstrated at Hb A1c 
levels of 9% or more. 
iv) Body Mass : 
Low body mass is a independent risk factor for TB. 
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Immune dysfunction in diabetes17 : 
A probable cause of increased incidence of pulmonary Tuberculosis in DM 
could be defect in host defenses and immune cell function. 
The immune derangements predominantly involve the cell mediated 
immunity arm of the immune system. Also the degree of Hyperglycemia has been 
found to have a district influence on the microbicidal function of macrophages, 
with even brief exposures to blood sugar level of 200mg% significantly 
depressing the Respiratory burst of these cells. 
Multiple pulmonary physiologic abnormalities have also have also been 
documented in diabetics that contributes to delayed clearance of the spread of 
infection in the host infection with Tubercle bacilli leads to further alteration in 
cytokines, monocytes , macrophages and CD4/CD8 T cell populations. The 
balance of the T-lymphocyte subset CD4 and CD8 plays a central role in the 
modulation of host defenses against mycobacteria and has a profound influence on 
the rate of regression of active pulmonary tuberculosis. 
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List of defect in diabetics immunologic make up and physiologic 
pulmonary functions. 
Immunologic abnormalities in 
diabetes 
Pulmonary Physiologic dysfunction 
in diabetes. 
Abnormal Chemotaxis adherence, 
phagocytosis and microbicidal 
function of polymorph. 
Diminished bronchial reactivity. 
Decreased Peripheral monocytes with 
impaired phagocytes. 
Reduced elastic Recoil and lung 
volumes. 
Poor blast transformation of 
lymphocytes. 
Reduced diffusion capacity. 
Defective C3 opsonic function.  Reduced ventilator Response to 
Hypoxemia 
 
Cellular immunity : 
The levels of interferon gamma and interleukin 12 productions in diabetic 
patients were significantly lowered. These cytokines production were significantly 
reduced in patient with TB with DM than TB alone. 
The levels of IL-12 in tuberculous patients were highest. But the patients 
cytokines in TB and DM was lowest. The low interferon gamma correlates with 
DM control. The period for Negative control finding in TB and DM patients under 
poor control were compared with those with TB alone18. 
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Cellular immunity of Pulmonary Tuberculosis in patients with Diabetes. 
(Russian-Rroblemy – 1997)  
The parameters of cellular immunity were studied in 64 patients with 
pulmonary tuberculosis developed in the presence of Type I DM compared with 
the patients with pulmonary TB alone. 
Patients with concomitant abnormalities showed higher depression of 
cellular immunity appeared as fewer T-lymphocytes are decreased capacity for 
blast cell transformation than those with TB alone11. 
Several  groups of investigators have found patients with diabetes mellitus 
to be more susceptible to tuberculosis, the overall increased risk being in the order 
of 2 to 3.5. Some have also documented an increased likelihood of lower lobe or 
multiple lobe disease, pleural effusion and cavitations. 
Numerous Risk factors have been indentified; among the more important 
ones are diabetes, silicosis, low body weight and smoking.  
A variety of disease conditions favour the development of active 
tuberculosis. These are HIV, DM and Silicosis, CRF etc14. 
In General, the organisms, that causes pulmonary infections are similar to 
those found in non diabetic population, however, gram Negative organisms, 
staphylococcus aureus and mycobacterium Tuberculosis are more frequent 
pathogens in DM12. 
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Pulmonary Complication of DM17 
The lung is not considered a target organ in diabetes mellitus. Many model 
demonstrated. 
1. Relative paucity of physical signs which may delay the diagnosis of 
TB in DM patients. 
2. Extensive caseation of lung tissue and cavitary lesion is more common. 
3. Middle and lower lobe predilection probably due to bronchial lymph 
node involvement. 
4. Limited pleural involvement. 
5. Greater tendency of hemoptysis. 
6. Less chance of extrapulmonary involvement. 
7. More cases of sputum +ve disease. 
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Clinical Features 
The clinical features and presentation of TB in most patients with diabetes 
are similar to those without, but unusual presentation haves been described. 
Higher incidence of Extrapulmonary tuberculosis and certain rare manifestations 
are  higher than in normal persons,  like laryngeal TB. 
The most frequently reported symptoms in studies of active pulmonary 
tuberculosis include cough (23-47%), fever (18-79%), weight loss (7-24%) and 
hemoptysis (8-9%). 
Symptoms of one disease often mimic those of the other. Loss of weight, 
Loss of appetite and Lassitude are common to both the disease. 
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An overview of Radiological lesion peculiarity in patients with combined 
diabetes and pulmonary Tuberculosis : 
Sosman and steidl reported that diabetic tuberculosis has a specific 
Radiological pattern consisting of confluent, cavitary, wedge shaped lesion 
spreading from the hilus towards  the periphery, predominantly in lower zone, to 
the extent of around 20%. 
Marias observed lower lung field tuberculosis in 29% of patients with DM, 
as compared to 4.5% in the non DM patients. However; in other studies, cavitary 
disease and multiple lobe involvement was found to be more common in patients 
with pulmonary tuberculosis with DM. 
3Lower lobe pulmonary TB is not uncommon and the report appeared from 
literature from time to time. The earliest report are those of KIDO in 1886 and 
FOWLER in 1888, who noted the vulnerability of the spaces of lower lobe with 
the evidence  of  postero-anterior and lateral skiagram of the chest. 
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Management of Tuberculosis in DM patient1 : 
1. Proper Care. 
2. Patient with poor diabetic control should be hospitalized for stabilizing  
their blood sugar level. 
3. Ideally, insulin should be used to control blood sugar level. 
4. OHA should be used only in cases of mild diabetes. Drug interaction with 
Rifampicin should be kept in mind. 
5. Glycemic equilibrium is essential for the success of ATT and must be 
achieved in every patient with co-existent disease. The goal of therapy are 
: fasting plasma gluscose < 120 mgs and glycated Hb% <7%. 
6. Vigorous and good chemotherapy is essential, monitoring for adverse 
effect, particularly of hepatic and nervous system should be done. Use of 
potentially Neuropathic agent (INH) in patients with peripheral 
Neuropathy demands special consideration with mandatory administration 
of pyridoxine. 
7. Duration of chemotherapy is entirely dependent up on the control of 
diabetes and responses of the patient to treatment. A longer treatment 
course may be needed. 
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8. Supportive therapy for diabetes must be actively pursued.  
9.  Management of co-existent illnesses, malnutrition and rehabilitation of the 
alcoholic diabetics remain of prime concern. 
10. If the DM is well controlled, response to ATT is same as non diabetic 
groups. However, if not under strict control, treatment of TB is often 
ineffective. Patients with type II DM on oral therapy may need of 
supplementation of insulin replacement. Type I patients may require 
intensified insulin treatment. Adequate insulination is important as it . 
a. Restore host defense response to infection. 
b. Restore anabolic process. 
c. Restore appetite and thereby improve weight. 
d. Restore the sense of well being6. 
Many ATT drugs are metabolized in the liver. Rifampicin is crucial for the 
success of ATT regimen, it induce hepatic enzyme and inactivate 
sulphonylureas, metabolized by the liver, these drugs may become less 
effective and should preferably be avoided. 
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Some ATT have metabolically affect the endocrine affect of endocrine 
effect of DM, which can affect the diabetic status eg. Pyrazinamide. Rifampicin  
can  impair Renal function and cause acute Renal failure even within few weeks 
of starting therapy. INH & Rifampicin both lead to abnormal Vit. D metabolism 
and  hypocalcemia.  PAS therapy is associated with Hypoglycemia. 
The Recommendation for treatment of TB with DM patients ie. Four drug 
regimen (Rifampicin / INH/ Ethambutol / Pyrazinamicle) for 2 month intensive 
phase followed by 4 months of continuation phase. Patient should be monitored 
carefully, because danger of drug interaction. Based on clinical experience some 
patient not response to usual 6 months Regimen, they should be prolonged to nine 
months or even one year Regimen. 
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Prophylaxis 
All diabetics required regular medical examination and bi-annual chest 
radiograph. This should be followed more vigorously in patients who are more 
than 40 yrs of age or with weight less than 10% of the ideal body weight.  
Any diabetic –who suddenly develops cough, loss of weight, abnormal 
chest radiograph or needs increasing dose of insulin to control blood glucose 
should be investigated for presence of TB. 
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SUBJECT AND METHODS 
 
 
A total of 100 cases of Diabetic patients attending medicine OPD/IPD who 
has chest symptoms of duration ranging from 3wks to 6 months with age group 
ranging from 18 years  to 79 years of both male and females were selected. 
Screening for pulmonary tuberculosis is to be done on these patients. 
Place of Study 
Out patients & Inpatients department 
Department of Medicine 
Stanley Medical College, 
Chennai – 1. 
Period of Study : 
April 2010 – November 2010. 
Inclusion Criteria 
Adult patients ranging from 18 years to 79 years of age of both sex with 
Diabetes mellitus on Treatment 
 
29

Exclusion Criteria 
1. Patients with previous history of pulmonary Tuberculosis. 
2. Patients with previous history of Extra Pulmonary Tuberculosis and 
exposure to ATT.  
Study Method : 
Prospective observational Study. 
Subjects : 
A total of 100 known diabetic patients, taking treatment in medicine 
department, who have chest symptoms of duration ranging from 3 weeks to 6 
months with age group ranging from 18 to 79 years of both sexes were selected. 
They underwent screening for pulmonary Tuberculosis. 
The study was carried out at Govt. Stanley Medical College Hospital, 
Medicine department with the active co-ordination and participation of chest 
clinic and other departments from April 2010 to November 2010. For the purpose 
of the study of known diabetic patient getting treatment in our hospital with chest 
symptoms like cough with expectoration (>3 weeks), chest pain  , hemoptysis, 
fever were screened for the occurrence of TB, who have not been previously 
investigated.  
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The methodology comprised of history of symptomatology of TB, physical 
examination and laboratory investigation of Urine and Blood analysis for glucose, 
blood count, ESR, X-ray chest, Sputum AFB and mantoux. 
Particulars of subjects with Diabetes alone and combination of Diabetes 
with   pulmonary Tuberculosis - Number and Sex Ratio. 
Number of Subjects Diabetes 
Diabetes with 
Pulmonary TB 
74 26 
Sex 
37 20 
Male 
Female 37 6 
Ratio M :F 1:1 3:1 
 
History : 
Enquiry of the subjects based on symptomatology, detailed history 
including the duration of both DM and TB. The average duration of the diabetes 
prior to the onset of TB varied between sexes. The duration of DM among the 
patients, who had pulmonary TB ranges from minimum of 1 year to maximum of 
20 years. 
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Symptomatology; 
Subjects with DM and also with a combination of DM and pulmonary TB 
were presented with the following chest symptoms of duration ranging from 3 
weeks to 6 months. Underwent the investigation for confirming the diagnosis of 
pulmonary TB. 
Details of Symptomatology investigated for TB: 
Chest Symptoms presented in the study groups. 
Cough Chest pain 
Hemoptysis Loss of appetite and weight 
Fever Others.
Physical Examination 
All the patient with established diabetes mellitus underwent physical 
examination which comprised, General Examination, Respiratory system 
examination and other system examination. 
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Particulars of physical examination of subjects. 
Nature of Examination Particulars 
General Examination Pulse, Blood Pressure, Temperature 
Built of individual, Height, Weight 
Body Mass index (BMI), Pallor, 
Clubbing, lymph node, cyanosis, leg 
edema. 
Respiratory System Examination  Upper respiratory tract, Trachea, Chest 
deformity, Respiratory Movement, 
vocal fremitus, percussion, 
Auscultation, vocal resonance etc. 
Other system examination Cardiovascular, Abdomen and Nervous 
System. 
 
Mantoux test : 
This test was done by using purified protein derivative (PPD) RT 23 of 
one Tuberculin unit, injected on the volar aspect of the left forearm intradermally. 
Result was observed after 48 to 72 hours. As indurations of diameter 10mm or 
more was considered to positive. 
X-ray Chest : 
X-Ray chest Postero – Anterior view was taken for all patients in the study 
groups and lateral view was taken in selected cases. Number of Zones involved, 
nature of the lesion like infiltration, cavitation, consolidation and fibrocavity was 
documented. 
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The upper zone corresponds to an area between the apex of the lung and to 
a line drawn at a Lower border of second costal cartilage. The middle zone  in 
between upper zone and fourth costal cartilage. Below the middle zone is the 
lower zone. Depending on the radiological lesion, pulmonary TB can be divided 
radiologically. 
1. Early tubercular infiltration.. 
2. Pneumonic or broncho pneumonic[consolidation] lesions 
3. Cavitary lesions. 
4. Disseminated lesions. 
5. Miliary lesions. 
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Study Results and Discussion  
The results of the investigation are classified under following headings for 
the purpose of discussion. 
A. Subject under study : 
The study group comprised of 100 subjects who had established diabetes 
mellitus taking treatment at medicine department presented with the complaints of 
chest symptoms underwent screening for evidence of pulmonary TB. Out of 100 
subjects 26 were found to be suffering from pulmonary TB. The Remaining 74 
subjects had diabetic alone who responded for routine antibiotics for their chest 
symptoms. The spectrum of distribution in terms of sex and age groups are 
presented here. (Table-1). 
Table - 1 
Number, Sex and age group Breakup of subjects with combination of Diabetes 
and pulmonary  Tuberculosis against Diabetes alone. 
Number of Subjects Diabetes 
Diabetes with 
Pulmonary TB 
74 26 
Sex 
37 20 
Male 
Female 37 6 
M :F Ratio 1:1 3.3:1 
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 Diabetes alone TB with DM 
Age 
Group Male Female Total Male Female Total 
Below 9 - - - - - - 
10 -19 - 1 1 - - - 
20-29 - - - - - - 
30-39 2 0 2 1 0 1 
40-49 4 8 12 2 0 2 
50-59 11 10 21 5 2 7 
60-69 12 11 23 8 3 11 
70-79 8 7 15 4 1 5 
Total  37 37 74 20 6 26 
 
Here incidence as well as prevalence are same in this study. The subjects 
studied for the incidence / prevalence of pulmonary TB among 100 diabetes 
patients, 26% were with evidence of pulmonary Tuberculosis, with Respect to sex, 
male account for three times that of female , where as the sex ratio is about equal 
in diabetes alone. This difference, suggests that, male are expected to have a 
greater risk to TB infection than females. Even though the number of subjects are 
enough to purpose a generalization. The causes may be many and also varied. 
Considering the economic strategic of the subjects, it may be associated under an 
environment peculiar to industrial area. 
Age group break up presents a pattern, in which difference between the 
combination of TB with DM and diabetes alone can be made out, for instance the 
frequency diagram shows a sharp, peak for the age group of 60-70 years and the 
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high valve and have a narrow range in either side is 30-40 years and 70 years and 
above for cases of pulmonary TB with diabetes. But in the diabetes alone, patients 
present a frequency diagram entirely different. The trend is conspicuous by the 
absence of any high peak, a plateau of value can be noted widening the age group 
ranges between 40 years to 80 years. This at once suggests that the susceptibility 
is high in increased age in duration of diabetes. 
B. Symptomatology: 
In term of symptomatology, the subject suffering with diabetes and 
pulmonary TB and diabetes alone may be subjects symptoms wise,   presented in 
table-2 . 
Polyuria and polydypsia are quite common symptoms of Diabetes. Among 
the study group populations with diabetes alone, and combination with pulmonary 
Tb, the symptoms are presented in table-2. 
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Fever Chest pain 
Loss 
of 
appet
ite 
 Loss of 
weight Others 
Diabetes 
alone Total 
No; 74 
21 17 14 1 74 0 19 10 07 0 2 
% of 
Symptoms 28.37 22.97 18.91 1.35 100% 0 25.67 13.51 9.45 0 2.70 
DM with Pul 
TB Total No. 
26 
20 15 16 2 26 7 15 4 14 4 2 
% of 
symptoms 76.92 57.69 61.53 7.69 100% 26.92 57.69 15.38 53.84 15.38 7.69 
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Analyzing the symptomatology of the study group of diabetes with TB, 
apartfrom the symptoms of diabetes alone, these subjects presented with cough, 
fever, chest pain, hemoptysis, loss of appetite and of loss of weight with a 
percentage of 100, 57, 15, 26, 53 and 15 respectively. In contract to diabetes alone 
group, subjects with TB had fever and hemoptysis. The hemoptysis account 26% 
where as it is zero in diabetes alone, similarly loss of appetite and loss of weight 
account for 53% and 15% respectively, loss of weight is not a feature in diabetic 
alone and loss of appetite is not so high in diabetic alone patients. Any patients 
with established diabetes who complaints of loss of appetite and loss of weight 
carries significance and investigation is to be carried out to rule out Tuberculosis. 
C.BLOOD COUNT DATA; 
Blood count data – total and differential counts are comparing between 
combination of DM with pulmonary TB and Diabetes alone(Table-3,4). 
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Table -3 
Total Counts and ranges in subjects with DM and pulmonary TB as against 
Diabetes alone. 
Disease Total Leucocytes count 
cells/cumm 
Range Cells / cumm 
DM with Pulmonary TB 6878 4200-11300 
Diabetes alone 6337 4200-11500 
 
Table -4 
Differential Counts and range in subjects with Diabetes and Pulmonary TB 
as against Diabetes alone. 
 
Differential Counts and range 
Polymorphs % Lymphocytes % Eosinophils / 
monocytes% 
DM and 
Pulmonary TB 
66 
(55-82) 
33 
(24-45) 
2 
(0-10) 
DM alone 
68 
(50-82) 
31 
(15-48) 
2 
(0-10) 
 
Blood Glucose values as also insulin requirements and duration of diabetes 
with pulmonary TB and Diabetes alone (Table-5). 
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Table -5 
Disease Sex 
Bl. Glucose 
mgs% F-
fasting/PP-
post prandial 
Insulin 
requirement 
(Units) 
Duration of 
diabetes 
(years) 
Diabetes with 
Pulmonary. 
TB 
 
 
M : 7 
F : 4 
 
Total No: 11 
 
Male 
 
 
 
Female 
 
 
Mean 
(F) – 283 
PP – 387 
 
 
(F) - 298 
PP – 387 
 
(F) - 291 
PP – 387 
 
40 
 
 
 
39 
 
 
40 
7.4 
 
 
 
8.0 
 
 
7.7 
Diabetes 
alone 
 
 
M : 5 
F : 7 
 
Total No : 12 
 
Male 
 
 
 
Female 
 
 
Mean 
(F) – 137 
PP – 219 
 
 
(F) - 139 
PP – 211 
 
(F) - 138 
PP – 215 
21 
 
 
 
19 
 
 
20 
3.6 
 
 
 
3.9 
 
 
3.75 
 
D. Erythrocyte Sedimentation Rate : 
ESR values are assessed. The ranges estimated between 12 to 40 a mean value 
of 35 mm/hr in the cases of diabetes with pulmonary TB. The range of ESR value 
among diabetes alone study group extended between 5 and 40 mm/hr, with a mean 
value of 16mm/hr. though the value among combination of diabetes with 
pulmonary TB ranges high, this against a non specific criteria and as in the 
previous cases serves a 60/hr as a diagnostic tool. 
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Table -6 
Table showing blood glucose values and duration of Diabetes subjects on oral 
Hypoglycemic agents with pulmonary Tuberculosis and diabetes alone.  
Disease Sex Bl. Glucose (mgs%) 
Duration of Dm 
(yrs) 
Diabetes with 
 Pul TB 
 
M : 13  F :2 
 
Total No : 15 
Male  
 
 
Female 
 
Mean 
F – 232 
PP – 326 
F – 168 
PP – 314 
F – 200 
PP – 320 
9.5 
 
9.5 
 
9.5 
 
Diabetes alone  
 
M : 32  F :30 
 
Total No: 62 
Male 
 
Female 
 
Mean 
F – 141 
PP – 216 
F – 136 
PP – 212 
F – 138 
PP – 214 
4.7 
 
5.4 
 
5.05 
 
 
E. Sputum Examination for Acid Fast bacilli 
All 100 subjects screened for pulmonary TB were subjected to sputum 
Examination for Acid Fast Bacilli. Out of 100 subjects, 12 subjects were found to 
be positive for Acid Fast Bacilli. Out of which, 8 were males and 4 were females. 
These subjects were subjected to sputum examination for three times, Two spot 
specimen and one overnight collection. 
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Table -7 
Showing details of sputum Examination for AFB 
Aspects MALE FEMALE 
Sputum for 
AFB-Serial A B C D E F G H 1 J K L 
Sputum for 
AFB + + + + + + + + + + + + 
Bl. Glucose 465 300 317 400 330 296 323 292 364 282 305 465 
Insulin 
Requirement 45 40 35 45 45 36 38 36 45 36 45 45 
Age (years) 51 49 75 45 60 65 64 77 62 64 65 71 
 
Out of 12 sputum positive subjects, 11 were on insulin treatment, and 
remaining one patient, who was on oral Hypoglycemic agent treatment, also 
currently changed over to insulin. 
Among the sputum positive patients two had Radiologically lower lobe 
involvement with diffuse lesion, one had consolidation, five had cavitary lesion 
with surrounding infiltration, Four had infiltrative lesion. Most of all, are multiple 
zonal involvement, only one had left upper zone involvement. Radiological 
lesions correlated with uncontrolled hyperglycemia and sputum positivity with 
severity of clinical signs. 
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F. Mantoux test : 
Table -8 
Table showing Results of Mantoux test 
Male Female 
MX +ve Mx –ve MX +ve Mx –ve 
16 4 4 2 
 
     The Mantoux test results shows, 20 subjects were showed positive 
Mantoux, 6 were negatives. All positive Mantoux subjects had pulmonary 
Tuberculosis. Among the 6 negatives, apart from Radiological lesion two had 
sputum positive for AFB. So the Mantoux test is a sensitive for pulmonary TB 
like Non diabetes patients.  
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  Fig 2 :  Radiological features of patients with Diabetes and pulmonary 
Tuberculosis.  
 Total : 26  Male : 20  Female : 6 
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G. Body mass Index : 
TABLE-9. 
Table 9 showing, BMI variation between DM with pulmonary TB and DM 
alone. 
SUBJECTS BMI 
DM with pulmonary TB 18.92 
DM alone. 23.67 
 
It shows, Relatively underweight patients of Diabetes are more prone for 
pulmonary Tuberculosis infection 
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H.HbA1c VARIATION BETWEEN TB WITRH DM AND DIABETES 
ALONE; 
TABLE-10. 
Table 10 showing, HbA1c variation between DM with pulmonary TB and 
DM alone.  
SUBJECTS HbA1c in % 
DM with pulmonary TB 8.01 
DM alone. 6.47 
 
HbA1c results shows, that diabetes with pulmonary TB had more than 8% 
compared with diabetes alone, it shows less than 8%.It indicate uncontrolled 
diabetes more prone for pulmonary TB 
Table -11 
Number of lesions in subjects with DM and Pul. Tuberculosis. 
Side of Lesion 
SEX 
Total 
Male Female 
Bilateral 4 2 6 
Left 1 0 1 
Right 15 4 19 
 
46

Table -12 
Table showing Blood sugar levels and Radiological Features Correlation. 
S. No. Sex Bl. Glucose (mgs%) 
No. Zone 
involved  Type of lesion 
1. M 321 2 ® Consolidation 
2. M 210 1 ® Infiltration 
3. M 465 4 B/L Infiltration 
4. M 300 2 ® Consolidation 
5. M 193 1 ® Infiltration 
6. F 261 1 ® Infiltration 
7. M 317 2 ® Fibrocavity 
8. M 400 6 B/L Infiltration 
9. M 210 1 ® Infiltration 
10. F 364 6 B/L Infiltration 
11 F 282 2 ® Cavity 
12 M 297 2 ® Cavity 
13 M 330 3 B/L fibrocavity 
14 M 278 1 ® Infiltration 
15 M 312 2 ® Consolidation 
16 M 296 1 ® Infiltration 
17 M 323 3 ® Fibrocavity 
18 F 267 1 ® Infiltration 
19 M 292 2 ® Consolidation 
20 M 282 2 ® Infiltration 
21 F 305 2 ® Consolidation 
22 M 319 2 ® Cavity 
23 M 326 3 ® Cavity 
24 M 465 4 B/L Infiltration 
25 F 390 4 B/L Infiltration 
26 M 292 1 (L) Infiltration 
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Table -13 
Showing Number of Zones Involved  
No. of zones involved Number of Subjects 
One 8 
Two 10 
Three 3 
Four 3 
Five - 
Six 2 
 
Table -14 
Types of lesions and the pattern of distribution of subject with DM with 
Pulmonary TB. 
Type of Lesion Cases 
Break up of Side of Lesion 
Bilateral Right Left 
Infiltration 14 5 8 1 
Consolidation 5 - 5 - 
Cavity 4 - 4 - 
Fibrocavity 3 1 2 - 
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7All patients with tuberculosis were started 6 months ATT treatment 
according to the revised National Tuberculosis Control programme. The sputum 
positive tuberculosis patient were treated with DOTS Regimen, Containing 4 drug 
in the initial 2 months as intensive phase, are INH; Rifampicin; Ethambutol and 
pyrazinamide, and INH and Rifampicin for another 4 months as continuation 
phase. Diabetes was controlled with appropriate therapy (insulin) According to the 
continuous Bloodglucose monitoring. All sputum positive cases, subjected to 
sputum Examination for AFB after 2 months of intensive phase for monitoring of 
sputum conversion from positive to negative. 
To monitor conversion and detect possible emergence of drug resistance, 
sputum smear and cultures should be obtained monthly or at least after 2nd, 4th and 
6th months of therapy. With INH and rifampicin containing regimens, sputum 
should convert to negative within 2 months. If smear and culture results continue 
to be positive, after 2 months of therapy, emerging drug resistance and non-
compliance should be major concern. A new drug susceptibility test should be 
performed immediately.  
Unless drug resistance is documented, the regimen in use should be 
continued carefully under direct observation. If drug resistance occurs at least 2 
new drugs to which the organisms is sensitive should be added to the therapy and 
administered under direct observation. Additions of a single drug to therapy 
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should never be done since it will increase the risk of the rapid development of 
resistance to the new drugs. Bacteriological cultures and susceptibility tests should 
be performed at monthly intervals until the cultures become negative. Relapse of 
drug sensitive infection after adequate INH and Rifampicin containing treatment 
is very infrequent. For patients who have completed a standard regimen and had a 
satisfactory bacteriological response, follow up after completions of therapy is not 
necessary. In contrast, the patient with extensive disease, immunosuppressive 
patient, the persistence of radiological findings after therapy, or suspicious of poor 
patient compliance, are indications of prolonged follow up.  
Table -15 
Table showing interaction between severity of diabetes and Radiological 
lesions. 
1. Minimal Radiological lesion : 
 Single zone involved without affecting the other part. 
2. Moderate : 
More than one zone involved or Bilateral Single Zone involvement, 
but less than four zone involvement. 
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3. Far advanced : 
Bilateral Multiple Zone involved. 
Radiological 
lesions 
Diabetes 
150-250 mild 251-350 
moderate 
351 and above 
severe 
Minimal 3 5 - 
Moderate - 13 - 
Far advanced - - 5 
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CONCLUSION 
 
 
           The reason for choosing this topic for my study is diabetes is so prevalence 
in INDIA and worldwide, tuberculosis is also more common in India, so far the 
relation between these two common diseases may be useful for controlling 
pulmonary tuberculosis and helpful for the healthy life of diabetic population. 
          The followings are conclusion drawn from the above study of patients with 
DIABETES MELLITUS and PULMONARY TUBERCULOSIS. 
 
 
1. The prevalence of pulmonary Tuberculosis in diabetic patients is 26% 
2. The male and female ratio of pulmonary tuberculosis in diabetic patients is 
3.3:1. 
3. The age distribution of patients suffering from both pulmonary 
tuberculosis and diabetes mellitus ranges from 30-79 years, more in the 
age group between 60 to 69 years. 
4. Blood glucose is increased in combination of diabetes mellitus and 
pulmonary Tuberculosis compared with diabetes alone. 
5. Out of 26 Subjects, 12 subjects were sputum positive for Acid Fast bacilli, 
8 males and 4 females. 
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6. 20 subjects showed positive Mantoux, 6 were negatives. All positive 
Mantoux subjects, had pulmonary Tuberculosis. Among the 6 negatives, 
apart from Radiological lesion two had sputum positive for AFB. 
7. Radiological studies showed subject had 6 Bilateral lesions. Regarding to 
sex 4 males and 2 female had bilateral lesion, that is, 15.38% males and 
7.69% females had bilateral lesions. 
8. Severity of Radiological lesion correlated well with the severity of DM. 
9. Lower lobe involvement occurred in two patients, that is, 7.69%. 
10. The insulin requirement is more (double) in patient with pulmonary 
tuberculosis than Diabetes alone. 
11. Any diabetes patients showing sudden increase in insulin requirement is an 
indication to screen for pulmonary Tuberculosis. 
12. Patient on oral Hypoglycemic agents need insulin Replacement. 
13. Apart from 6 months course of Anti TB treatment, meticulous control of 
diabetes status is a must. 
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14. According to HbA1c results, uncontrolled diabetes has more prone for 
pulmonary tuberculosis. 
15. Early screening and good control of Hyperglycemia are essential in 
preventing the onset of tuberculosis. 
 
 
26%
Chart - 1 : Diagram Showing Percentage of Diabetes with pulmonary tuberculosis 
74%
against Diabetes alone.
Diabetes Diabetes with Pulmonary TB






	
 












	




 

	
 

 !"








#



 
	
100
26
57
15
53
15
0 20 40 60 80 100 120
Cough
Hemoptysis
Fever
Chest Pain
Loss of Appetite
Loss of Weight
Chart -3 : Symptoms of Pulmonary TB in DM in percentage
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PROFORMA 
 
 
 
1.   Name : 
 
2. Age : 
 
3. Sex : 
 
4. ID Number : 
 
5. Address : 
 
 
 
6. Diabetes : Y / N 
 
 How many yrs : 
 
 Type : 
 
 Treatment : 
 
 
 
7. Presenting Complaints : 
 
 Cough – 
 
 Hemoptysis – 
 
 Fever – 
 
 Chest Pain – 
 
 Loss of weight –  
 
 Others –  
 
 
 

8. General Examination 
 
 Conscious : 
 Orientation : 
 Anemia : 
 Clubbing : 
 Cyanosis : 
 Pedal edema : 
 Lymphadenopathy ; 
 
 
 Height :   Weight : 
 
 BMI : 
 
 
 
 
 PR :  Rate   / min 
   Regular / irregular 
   Vessel Wall thickening 
   Carotid bruit + / - 
 
 
 BP :  mm Hg 
 RR :    / min 
 
 
 
9.  CVS : 
 Apical Impulse : 
 Heart Sounds : 
 Murmurs : 
 
 
10. CNS : 
 
 
11. P/A : 
 
 
 
 

12. RS : 
 
 Upper respiratory tract 
  
 Trachea 
 
 Chest deformities 
 
 Respiratory Movement 
 
 Vocal fremitus / resonance 
 
 Percussion 
 
 Auscultation 
 
 
 
 
 
INVESTIGATIONS: 
 
1. Urine  R/E : 
   Albumin 
   Sugar 
   Deposits 
   Ketones 
 
 
2. RFT : 
   Urea 
   Creatinine 
   Electrolytes   Na  K  HCO3 
 
 

3. CBC : 
 
   TC  DC  ESR 
 
   Hb%  PCV  Platelets 
 
 
 
4. FBS 
 
 PPBS 
 
 
5. ECG : 
 
 
6. CXR PA View : 
 
 
 
7. Mantoux : 
 
 
8. Sputum AFB : 
 
 
9. HbA1C : 
 
 
10. CT Chest (if necessary) : 
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CONSENT FORM 
 
 
1. I agree to participate in the study titled “Study of current trends of 
prevalence and clinical spectrum of Pulmonary Tuberculosis in 
Diabetes Mellitus and its relationship with the glycemic status” 
 
2. I confirm that I have been told about this study in my mother tongue and 
have had the opportunity to ask questions. 
 
3. I understand that my participation is voluntary and I may refuse to 
participate at any time without giving any reason and without affecting my 
benefits. 
 
4. I agree not to restrict the use any data/results that arise from this study. 
 
 
Name of the participant: 
 
Signature/thumb print: 
 
 
 
Witness:                                                                                      Investigator  
S. 
No 
Name of  the 
Patient Age Sex 
Rx 
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TC DC P,L,E ESR X-ray chest CT chest 
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D
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Y
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1 Kulanthaiyesu 56 M 15 + - + + - - 27 Neg Neg 6.9 + 119 212 6700 70202 10/22 - - 6 
2 Razul Baig 48 M 20 + - - - - - 26 Neg Neg 6.5 - 118 186 7500 65352 5/7 - - 2 
3 Ramalingam 47 M OHA + - + - - - 21 +ve Neg 8.1 ++ 250 392 7650 70282 9/18 ® 
consolidatio
n 
® 
consolidat
ion 
8 
4 Abbas ali 63 M OHA + - - - - - 28 Neg Neg 6.4 - 150 187 5800 65341 8/20 - - 3 
5 Vijaya 46 F OHA + - - - - - 29 Neg Neg 6.9 + 100 233 4700 72062 10/22 - - 5 
6 Kadalaiyammal 62 F 0HA + - - -- + - 20 Neg Neg 7.1 + 170 221 6800 76222 8/32 - - 6 
7 Andalammal 56 F OHA + - - - - - 22 Neg Neg 6.5 - 40 170 6200 65341 5/12 - - 8 
8 Saroja 58 F OHA + - + - - - 26 Neg Neg 6.9 + 160 212 6800 55422 6/14 - - 10 
9 Nagarajan 60 M OHA + - + - - - 20 Neg Neg 7.9 + 180 240 4600 65350 18/32 ® Upper 
Zone 
infiltration  
- 11 
10 Ravi 51 M 45 + + + - + - 19 +ve +ve 9.1 +++ 419 512 5600 71281 12/23 B/L 
infiltration 
- 8 
11 Anandan 49 M 40 + - + - + + 15 +ve +ve 8.0 ++ 220 380 7900 69301 12/25 ® Upper& 
Middle zone 
consolidatio
n 
 4 
12 Balaraman 55 M OHA + - + + - - 21 +ve Neg 7.2 + 168 218 6400 55450 19/35 ® Upper 
zone 
infiltration 
- 15 
13 Mutharasi 53 F OHA + - - - + - 18 Neg Neg 7.5 ++ 180 342 6100 72262 6/14 ® upper 
zone 
infiltration 
- 8 
14 Gobinath 75 M 35 + - - - + - 16 +ve +ve 8.1 +++ 249 396 8600 60364 6/14 ® Upper& 
Middle zone 
fibrocavity 
- 6 
15 Valliammal 66 F OHA + - + - + - 24 Neg Neg 7.3 ++ 180 348 9800 80200 25/55 - - 5 
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16 Joney Basha 62 M OHA + - - - + - 26 Neg Neg 6.8 - 130 196 6300 82180 5/12 - - 15 
17 Sagunthala 48 F OHA + - - - - - 26 Neg Neg 6.7 - 126 190 6100 80200 10/22 - - 6 
18 Kuppusamy 68 M OHA + - + + - - 28 Neg Neg 6.8 + 113 220 5900 60373 5/12 - - 8 
19 Elumalai 58 M OHA + - - - - - 20 Neg Neg 6.5 - 107 160 8400 50482 26/40 - - 2 
20 Dilli 56 M 45 + + - - - - 20 +ve +Ve 9.2 +++ 322 477 4900 58384 26/40 B/L diffuse 
infiltration 
- 6 
21 Elumalai 49 M OHA + - + + - - 29 Neg Neg 7.2 ++ 212 280 8000 70300 10/16 - - 3 
22 Munusamy 59 M OHA + - + - + - 18 Neg Neg 7.2 +++ 180 240 6200 71281 15/35 ® upper 
zone 
infiltration 
- 8 
23 Sardha Beevi 62 F 45 + - + - + - 19 +Ve +Ve 8.1 +++ 312 415 5600 71290 10/25 B/L diffuse 
infiltration 
- 10 
24 Parvathi 52 F OHA + - - - - - 19 Neg Neg 6.6 + 120 191 4800 68311 8/024 - - 8 
25 Chellammal 64 F OHA + - - - + + 29 Neg Neg 6.5 + 102 212 6200 68302 5/12 - - 2 
26 Layal 62 M OHA + - - - - - 22 Neg Neg 6.5 + 128 216 5000 63371 6/14 - - 4 
27 Jamila 47 F OHA + - - -- - -- 20 Neg Neg 6.2 + 87 221 6100 52480 6/15 - - 3 
28 Lakshmi 64 F 36 + + - - + - 16 +ve +ve 7.6 ++ 244 320 8400 69274 10/26 ® Upper & 
middle zone 
cavity 
- 7 
29 Jothilakshmi 18 F 15 + - - + - - 27 Neg Neg 6.4 + 129 212 8900 80200 5/12 - - 2 
30 Kuppammal 63 F OHA + - - - + - 21 Neg Neg 6.3 + 124 208 6000 80200 5/20 - - 18 
31 Surya Narayanan 68 M OHA + - + - - - 21 Neg Neg 7.1 + 215 256 8500 60400 5/12 - - 16 
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32 Kalaivanan 63 M OHA + - - + - - 20 +ve Neg 7.8 ++ 225 368 6900 68320 6/15 ®  Upper & 
Middle zone 
cavity 
- 7 
33 Mannakatti 63 M OHA + - - - - - 20 Neg Neg 6.8 + 138 212 6000 63343 5/12 - - 2 
34 Janardhanan 60 M 45 + + - - - - 20 +ve +ve 8.2 ++ 280 380 1100 55450 10/32 B/L 
Fibrocavity 
B/;L 
Fibrocavit
y 
20 
35 Saravanan 39 M OHA + - + - - - 22 Neg Neg 7.4 + 239 317 6900 82153 3/7 ® Upper 
Zone 
infiltration 
- 70 
36 Jameed Basha 53 M OHA + - - - - - 27 Neg Neg 7.0 + 126 250 6600 60400 6/15 - - 6 
37 Ravi Selvam 38 M 24 + - - - - - 22 Neg Neg 6.4 - 106 178 4200 55414 7/15 - - 2 
38 Minnala 51 F 30 + - + - - - 26 Neg Neg 6.8 + 180 235 6700 75250 4/10 - - 4 
39 Lakshmi 56 F OHA + - - - - - 26 Neg Neg 6.4 - 128 180 8400 69254 16/24 - - 8 
40 Jayaraman 58 M OHA + - - - - - 27 Neg Neg 6.5 - 127 198 7100 72280 6/24 - - 4 
41 Dhamodharan 56 M OHA + - + + + - 20 Neg Neg 6.6 + 159 231 4500 68302 18/28 - - 2 
42 Mani 51 M OHA + - - - - - 29 Neg Neg 6.4 + 160 214 6000 70300 6/40 - - 8 
43 Mutharasan 57 M OHA + - + - - - 17 +ve Neg 8.0 ++ 282 342 11300 76240 18/40 ® upper & 
middle zone 
consolidatio
n 
- 7 
44 Bebi John 71 F OHA + - - - - - 22 Neg Neg 6.2 + 104 215 7100 75250 6/15 - - 4 
45 Mohan 47 M OHA + - - - - - 25 Neg Neg 6.4 - 123 189 6900 61354 10/19 - - 1 
46 Basker 65 M 36 + - + - - - 23 +ve +ve 7.8 ++ 225 368 7500 70300 2/15 ® upper 
zone 
infiltration 
- 5 
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47 Krishnaveni 46 F OHA + - + - - - 20 Neg Neg 6.4 + 126 184 6700 55405 5/20 - - 6 
48 Venkadakondaiy
a 
67 M OHA + - - - + - 21 Neg Neg 6.6 + 160 212 5800 72280 10/27 - - 2 
49 Thangavelu 59 M OHA + - - + - - 18 Neg Neg 6.4 - 120 186 6800 65251
0 
10/21 - - 10 
50 Samboornam 58 F OHA + - + - - - 20 Neg Neg 6.5 - 128 198 6400 62371 5/12 - - 4 
51 Paul mary 56 F OHA + - - - - - 27 Neg Neg 6.4 + 196 212 6700 70282 10/22 - - 6 
52 Parus 64 M 38 + + + - + + 15 +ve +ve 8.1 ++ 249 396 7900 69301 12/23 ® 
fibrocavity 
- 6 
53 Govindammal 68 F 20 + - - - - - 18 Neg Neg 6.2 - 112 186 7500 63352 7/15 - - 2 
54 Ambathika 47 F OHA + - + + - - 21 Neg Neg 7.2 + 212 295 7650 70282 9/18 - - 8 
55 Devan 54 M OHA + - + - - - 25 Neg Neg 6.4 - 125 190 6800 65341 9/20 - - 3 
56 Rajendran 57 M OHA + - - - - - 19 Neg Neg 6.1 + 100 233 4700 60355 10/22 - - 5 
57 Munusamy 67 M OHA + - - - - - 28 Neg Neg 6.4 - 158 245 6100 72262 19/35 - - 3 
58 Ramamoorthy 62 M OHA + - - - - - 20 Neg Neg 7.2 ++ 210 301 6800 76222 18/33 - - 6 
59 Muthu 60 M OHA + - - - -- - 23 Neg Neg 6.4 - 90 170 6200 65341 5/12 - - 2 
60 Amala 52 F OHA + - + - - - 20 Neg Neg 6.6 + 160 212 6800 55422 5/12 - - 2 
61 Priyamvada 50 F OHA + - + - - - 20 Neg Neg 7.4 ++ 214 320 4200 65350 6/14 ®  upper 
zone 
infiltration 
- 11 
62 Indira 60 F OHA + - + + - - 29 Neg Neg 6.5 + 160 220 5600 71281 8/32 - - 2 
63 Kumar 65 M OHA + - + - - - 21 +ve Neg 7.5 ++ 250 335 6400 55450 12/25 ® upper& 
middle zone 
consolidatio
n 
- 15 
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64 Jaya 70 F 16 + - - - - - 26 Neg Neg 6.4 - 132 197 8600 64324 6/14 - - 4 
65 Devaraj 38 M OHA + - - - - - 20 Neg Neg 6.6 + 180 248 9800 80200 4/10 - - 6 
66 Mumtaj 64 F OHA + - - - - - 26 Neg Neg 6.2 - 130 196 6100 80200 5/12 - - 6 
67 Susaimani 76 M OHA + - + - - - 26 Neg Neg 6.1 - 126 190 6100 80200 5/12 - - 6 
68 Yesodha 72 F 24 + - - - - - 28 Neg Neg 6.2 + 113 220 5900 60373 10/22 - - 6 
69 Mallika 53 F OHA + - - - - - 20 Neg Neg 6.0 - 107 156 8400 50482 5/12 - - 2 
70 Vijaya  58 F OHA + - - - - - 19 Neg Neg 6.8 + 212 218 8000 70300 9/9 - - 3 
71 Krishnan 72 M OHA + - - - - - 20 Neg Neg 7.6 ++ 200 364 4500 58324 26/40 ® upper& 
middle zone 
infiltration 
- 6 
72 Kasthuri 65 F 45 + + + + + - 18 +Ve +ve 8.1 ++ 239 371 6200 72280 15/36 ® upper& 
middle zone 
infiltration 
® upper& 
middle 
zone 
infiltration 
8 
73 Deen Mohamed 69 M OHA + - - - - - 19 +ve Neg 8.3 ++ 288 350 5600 71290 10/25 ® upper& 
middle zone 
cavity 
- 10 
74 Kalaiselvi 46 F OHA + - - - - - 19 Neg Neg 6.1 - 120 191 4800 68311 8/24 - - 20 
75 Maragatham 78 F OHA - - - - - - 29 Neg Neg 6.2 + 102 212 6200 68522 5/12 - - 10 
76 Sulochana 47 F OHA + - + + -  21 Neg Neg 6.2 _ 128 216 5000 63371 6/14 - - 4 
77 Kamrudeen 75 M OHA + - - - -  20 Neg Neg 6.3 + 87 221 6100 52481 6/15 - - 3 
78 Chandran 77 M OHA + - - - - - 16 Neg +ve 8.1 ++ 290 362 8400 69274 10/26 ® sided 
cavity  
- 7 
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79 Annabakiyan 72 M 30 + - + - - - Neg 23 Neg 6.2 + 128 216 5000 63371 6/14 - - 8 
80 Veerakumar 70 M OHA + - + - - - Neg 24 Neg 6.8 + 215 256 8500 60400 5/12 - - 6 
81 Narayanan 74 M OHA + - - - - - Neg 21 Neg 6.8 + 215 256 8500 60400 5/12 - - 6 
82 Vishalashi 71 F 45 - - - - - + Neg 20 +ve 9.2 +++ 419 512 6900 68320 6/15 B/L Upper 
&Middle 
zone 
infiltration 
- 7 
83 Senthamarai 61 F OHA + - - - - - Neg 20 Neg 6.3 + 138 212 6000 63343 5/12 - - 2 
84 Rajesh 73 M OHA + - - - - - Neg 21 Neg 9.0 +++ 360 420 11000 55450 10/32 B/L 
infiltration 
- 12 
85 Eswaran 46 M OHA + - - - - - Neg 22 Neg 6.4 + 168 218 6900 82153 3/7 - - 2 
86 Riaz 58 M OHA + - - - - - Neg 22 Neg 6.6 + 126 250 6600 60400 6/15 - - 4 
87 Malliga 62 F OHA + - - - - - Neg 31 Neg 6.4 + 106 178 4200 55414 7/15 - - 2 
88 Victoria 74 F 18 + - - - - - Neg 21 Neg 6.4 _ 180 235 6700 7525 4/10 - - 3 
89 Chandhran 63 M OHA + - - - - - Neg 26 Neg 6.4 - 128 180 8400 69256 16/24 - - 4 
90 Savithri 75 F OHA + - - - - - +ve 27 Neg 6.1 - 127 198 7100 72280 6/24 - - 4 
91 Chitra 70 F OHA + - - - - - Neg 20 Neg 6.2 + 150 231 11500 63352 18/28 - - 4 
92 Shanthi 48 F OHA + - + - - - Neg 19 Neg 6.3 + 160 214 8000 70300 18/40 - - 5 
93 Ramesh 42 M 36 + - + - + - Neg 17 Neg 7.8 ++ 250 335 11300 70300 18/40 L-upper 
zone 
infiltration 
L-upper 
zone 
infiltration 
7 
94 Alima 66 F OHA + - - - - - Neg 32 Neg 6.2 + 105 215 7100 76240 6/14 - - 8 
95 Krishnan 54 M OHA + - - + - - Neg 25 Neg 6.0 - 123 189 6900 75250 6/15 - - 1 
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96 Umamaheswari 62 F OHA + - - - - - Neg 24 Neg 6.4 ++ 142 224 7500 61354 10/19 - - 2 
97 Raman 65 M OHA + - - - - - Neg 28 Neg 6.2 + 160 212 5800 70300 2/15 - - 2 
98 Somasundharam 72 M 15 + - - - - - Neg 26 Neg 6.4 + 140 286 6800 55405 5/10 - - 6 
99 Rajendran 76 M OHA + - - - - - Neg 22 Neg 6.2 - 128 198 6400 72280 10/27 - - 3 
100 Krishnakumar 70 M OHA + - - - - - Neg 22 Neg 6.1 - 126 184 670 622510 10/21 - - 6 

